In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue (eMatrixCO2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01026662
Recruitment Status : Unknown
Verified November 2014 by Syneron Medical.
Recruitment status was:  Active, not recruiting
First Posted : December 4, 2009
Last Update Posted : December 2, 2014
Information provided by (Responsible Party):
Syneron Medical

Brief Summary:

This study will:

Evaluate the in vivo effects of treatment with eMatrixCO2 and to determine the dynamics of their development over time following treatment.

Condition or disease Intervention/treatment
Abdominoplasty Procedure: Ablation and skin resurfacing Device: eMatrixCO2

Study Type : Observational
Estimated Enrollment : 5 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue
Study Start Date : November 2009
Actual Primary Completion Date : April 2010

Group/Cohort Intervention/treatment
Subjects scheduled for abdominoplasty surgery
Procedure: Ablation and skin resurfacing
Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
Device: eMatrixCO2

Primary Outcome Measures :
  1. Histological and molecular assessment of tissue taken following treatment with different parameters and at various time points [ Time Frame: Immediate, 1, 3, 10, 30 days ]
  2. Record number and type of any AE during the study [ Time Frame: Throughout study ]

Biospecimen Retention:   Samples Without DNA
Abdominal Skin tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy Subjects scheduled for an abdominoplasty surgery

Inclusion Criteria:

  • Informed consent agreement signed by the subject.
  • Healthy males or females older than 21 to 60 years of age.
  • Fitzpatrick skin type I-V (Although the systems are cleared for all skin types I-VI, it is recommended to use the Matrix applicators on skin types I - V).
  • Willingness to follow the treatment and follow-up schedule and the post-treatment care.
  • For female candidates - post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide, or abstinence).

Exclusion Criteria:

  • Pregnant and/or breastfeeding.
  • Having a history of diseases stimulated by heat, such as recurrent Herpes
  • Simplex in the treated area, unless treatment is conducted following a prophylactic regimen.
  • Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) one week before and after each treatment session.
  • Use of retinoids, antioxidants or therapeutic skin nourishing supplements at medicinal concentration within 2 months of treatment or during the study and oral retinoids within 6 months of the study.
  • Having received treatment with light, RF or other devices in the treated area within 6 months of treatment or during the study.
  • Having received collagen/fat injections or other methods of augmentation with injected or implanted material in the treated area within 9 months of treatment or during the study.
  • Having received Botox in the treated area within 6 months of treatment or during the study.
  • Having undergone any other surgery in the treated area within 6 months of treatment (or more if skin has not healed completely) or during the study.
  • History of keloid scarring or of abnormal wound healing.
  • Suffering from current or history of significant skin conditions in the treated area or inflammatory skin conditions, including, but not limited to: active acne, excessive skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage), varicella scars, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
  • History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
  • History of epidermal or dermal disorders (particularly if involving collagen or microvascularity).
  • History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
  • Suffering from hormonal imbalance, as per the Investigator's discretion.
  • Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
  • Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including actinic keratosis, presence of malignant or pre-malignant pigmented lesions.
  • Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), or pertinent neurological disorders.

Vascular lesion, tattoo or permanent make-up in the treated area.

  • Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
  • Participation in a study of another device or drug within three month prior to enrollment or during the study.
  • As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01026662

United States, Texas
SouthWestern Medical Center
Dallas, Texas, United States, 75390-8843
Sponsors and Collaborators
Syneron Medical

Responsible Party: Syneron Medical Identifier: NCT01026662     History of Changes
Other Study ID Numbers: eMatrixCO2 Preab
First Posted: December 4, 2009    Key Record Dates
Last Update Posted: December 2, 2014
Last Verified: November 2014

Keywords provided by Syneron Medical:
Aesthetic dermatology